The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
BSH 2018 | Hodgkin lymphoma: difficulties faced in geriatrics
At the British Society for Haematology (BSH) 2018 Annual Scientific Meeting, held in Liverpool, UK, Wendy Osborne, MBBS (Hons), MRCP, FRCPath, of Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle, UK, discusses the difficulties we face in treating Hodgkin Lymphoma (HL) within the geriatric population. In part, this is contributive to the heterogeneity of elderly patients with HL, making it difficult to ascertain a catch-all treatment decision. To resolve this, Dr Osborne suggests the utilization of geriatric assessment tools such as comorbidity scoring to resolve treatment decisions, including assessing how common treatments such as ABVD and bleomycin will affect an older population. Particularly, she notes the detrimental consequences peripheral neuropathy can have, which may not affect a younger cohort as extensively.
